跳至主要内容
临床试验/NCT01315093
NCT01315093已完成2 期

Role of Heparin in Poor Responders Undergoing In Vitro Fertilisation

National and Kapodistrian University of Athens1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2010年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
50
试验地点
1
主要终点
no of oocytes retrieved

研究概览

简要总结

The addition of heparin increases pregnancy outcome parameters in poor responders undergoing In Vitro Fertilisation (IVF)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
25 Years 至 43 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • poor responders (age>40, abnormal ovarian test, </=4 oocytes in previous cycle with conventional stimulation)
  • infertility, indication for IVF
  • no contraindications for heparin

排除标准

  • 未提供

研究组 & 干预措施

Heparin, Low-Molecular-Weight group

Experimental

LMWH was administered during an IVF cycle using either the GnRH - agonist or antagonist protocol in poor responders. Drug was started at the beginning of the cycle and stopped at the time of pregnancy test if negative, or continued if pregnancy occurred until the 32th weeks of gestation

干预措施: Heparin, Low-Molecular-Weight (Drug)

Non Heparin, Low-Molecular-Weight group

Active Comparator

IVF cycle using either the GnRH - agonist or antagonist protocol in poor responders.

干预措施: no heparin (Drug)

结局指标

主要结局

no of oocytes retrieved

时间窗: egg recovery, 2 years

\>2 between groups

次要结局

  • miscarriage rate(2 years)
  • clinical pregnancy rate(2 years)
  • live birth rate(2 years)
  • cancellation rate(before ET, 2 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Siristatidis Charalampos, MD, PhD

Assistant Professor, Director of the ARU

National and Kapodistrian University of Athens

研究点 (1)

Loading locations...

相似试验